Regenerative therapies could be the key in the future of osteoarthritis treatment, according to the doctor who specializes in orthopedic surgery and traumatology, Dr. Ramón Cugat, who is convinced that the use of plasma rich in growth factors or stem cells could help as a curative or preventive treatment in moderate arthrotic lesions.
“A lot of work is being done in the world in this field. There are large studies, and you are seeing that both growth factors and stem cells are going to play a very important role in the future, and quite possibly synergistic. It is feasible that the combination of the two therapies will help us to cure or prevent moderate degrees of osteoarthritis”, explained to Europa Press the President of the Board of Trustees the García Cugat Foundation and responsible for the García Cugat Foundation Medical and Regenerative Surgery Chair and the CEU Cardenal Herrera University of Valencia.
These therapies, which are still in many cases under investigation, “are based on using our own resources, our own energy sources, to cure our body’s injuries,” either because they stimulate or slow the repair or healing of degenerate, unstructured or broken tissues.
In the case of osteoarthritis, consider that there are currently therapies such as chondroitin sulfate and glucosamine that help treat cartilage in degeneration in osteoarthritis. “Studies have been done, and although not definitive, we can see that there is a contribution that goes very well to some people,” he says, betting on the study of his contribution, especially considering that he can exercise protection of the chondrocytes surrounding the extracellular matrix.
This is one of the topics that will be discussed in the IV Days of the García Cugat Foundation for Biomedical Research, which will be held this Saturday, and where we will discuss and discuss all the clinical work and research that has been done during this year on regenerative medicine.
During this meeting two lines of research will be discussed in which they work from the Foundation, which are initially linked with the field of veterinary medicine, as a first step within research and as a future of broader studies in the human field.
On the one hand, work is being done on growth factors in traumatology, it is the application of proteins and cytokines specific to the healing of an injury in the human body from the collective tissue, i.e. bone, tendon, muscle and ligament.
Research into growth factors is, possibly within regenerative therapies, among the most advanced treatments, as it is “currently used in various fields”; thus is seen in skin regeneration therapies, and especially in cosmetic and plastic surgery, and regenerative tissues such as mastectomies; it is also being used in orthopedic, bone or muscle surgery, ophthalmology and general surgery, among others.
“It has multiple applications right now because we are using a resource of our own body. They are proteins that run through our circulatory system, they are nothing strange ours, it has been seen that they have a paracrine action that stimulates the cells to regenerate in the areas where there is an injury”, explains.
The second line of research is that of stem cells, which can be removed from various tissues of the body, “although those that are most in vogue are those that are taken out of the bone marrow and, on the other hand, the fat of the body”, and, in these case, “they can also serve as regenerating elements of our injured tissue”.
“Today we do not know if bone marrow or fat will be better, so here we are researching both cambos,” he said, pointing to an ongoing project that evaluates the treatment of osteoarthritis by using mesenchymal cells obtained from adipose tissue and growth-rich plasma already being developed in animals.
With regard to osteoarthritis we want to see if its application has a better indication when a sports (traumatic) injury has occurred or when progressive (arthrosic) wear occurs. “In these days we want to work and discuss when your indication will be better and you will have a better future for the articulation, because it has been seen that in osteoarthritis it could be more palliative,” explains the doctor, who warns that research in this area is still at a very early stage.
This Saturday, in addition to the results of the study on the clinical effect of the application of mesenchymal cells versus growth factors in the dog with osteoarthritis, a clinical trial on mesenchymal fat cells in cartilage lesions will be discussed and presented ‘Arthrotest’, the first genetic test – based on the genotyping of SNPs and clinically validated – to predict the progression of the
This test, which allows to know the genetic predisposition of each patient to suffer a rapid progression of primary knee osteoarthritis, is a step in the field of personalized medicine that will allow a significant economic savings because those patients who are at increased risk of being recipients of a knee prosthesis can take preventive measures to avoid the ailment , both pharmacological and lifestyle.
Source: Infosalus.com – Europa Press